Masaki Ichikawa
- Pharmaceutical Science top 2%
- Drug Solubulity and Delivery Systems 3
- Physiology top 5%
- Nitric Oxide and Endothelin Effects 3
- Ophthalmology top 5%
- Glaucoma and retinal disorders 9
- Spectroscopy top 5%
-
- Anesthesia and Neurotoxicity Research 2
-
- Retinal Development and Disorders 6
-
- Neuropeptides and Animal Physiology 3
-
- Gastroesophageal reflux and treatments 2
- Gastrointestinal motility and disorders 2
- Co-authors
- Sumio WatanabeYasuo MiyakeMasanori KayanoIkuo KushidaNaoki AsakawaTakeshi MiyakawaToshinobu MiwaYoshiko Iwasaki
- Journals
- Development (2 papers)Brain Research (1 paper)Journal of Pharmaceutical Sciences (3 papers)
- Partner nations
- JapanUnited States
In The Last Decade
Masaki Ichikawa
24 papers receiving 708 citations
Peers
Comparison fields: 5 of 87
- Pharmaceutical Science 181
- Physiology 108
- Ophthalmology 136
- Spectroscopy 152
- Developmental Neuroscience 34
Countries citing papers authored by Masaki Ichikawa
This map shows the geographic impact of Masaki Ichikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaki Ichikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaki Ichikawa more than expected).
Fields of papers citing papers by Masaki Ichikawa
This network shows the impact of papers produced by Masaki Ichikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaki Ichikawa. The network helps show where Masaki Ichikawa may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Masaki Ichikawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2018 | 66 | |
| 3 | Omidenepag isopropyl, a selective EP2 agonist, shows additive intraocular pressure (IOP)-lowering effects when used concomitantly with existing anti-glaucoma drugs in animal models | 2017 | 1 |
| 4 | 2010 | 3 | |
| 5 | 2005 | 24 | |
| 6 | 2005 | 10 | |
| 7 | 2004 | 21 | |
| 8 | 2004 | 5 | |
| 9 | 2004 | 5 | |
| 10 | 2004 | 11 | |
| 11 | 2003 | 10 | |
| 12 | 2002 | 59 | |
| 13 | 2001 | 74 | |
| 14 | 2001 | 13 | |
| 15 | 1997 | 5 | |
| 16 | 1996 | 5 | |
| 17 | 1994 | 1 | |
| 18 | 1991 | 40 | |
| 19 | 1991 | 98 | |
| 20 | 1987 | 133 |
About Masaki Ichikawa
Masaki Ichikawa is a scholar working on Ophthalmology, Gastroenterology and Pharmaceutical Science, having authored 25 papers that have together received 756 indexed citations. Recurring topics across this work include Glaucoma and retinal disorders (9 papers), Retinal Development and Disorders (6 papers), Nitric Oxide and Endothelin Effects (3 papers), Drug Solubulity and Delivery Systems (3 papers), Neuropeptides and Animal Physiology (3 papers), Gastroesophageal reflux and treatments (2 papers), Gastrointestinal motility and disorders (2 papers) and Anesthesia and Neurotoxicity Research (2 papers). The work is most often cited by research in Pharmaceutical Science (181 citations), Physiology (108 citations) and Ophthalmology (136 citations). Masaki Ichikawa has collaborated with scholars based in Japan and United States. Frequent co-authors include Sumio Watanabe, Yasuo Miyake, Masanori Kayano, Ikuo Kushida, Naoki Asakawa, Yasuo Miyake, Takeshi Miyakawa, Toshinobu Miwa, Yoshiko Iwasaki and Tomoyuki Okutsu. Their work appears in journals such as Development, Brain Research and Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.